Dendreon Corp fka DNDNQ

[nerdseeksblonde]

We agree on many of these points,
but please see some of my other posts
specifically those supporting the FDA decision.

DNDN needed management that understands the importance
of details- maybe their CEO doesn't need to
know what TOF-MALDI-MS stands for but someone who
can appreciated that small things could matter
could be a big plus ( the lack of an in vivo target
is a big deal- either they aren't looking properly
and it really does generate PAP responses [ not
out of the questions ] or it uses a different mechanism
[ including attack on conformational epitope- note
that blonde highlights change shape ] or it
doesn't work [ which they may even be able to prove in vitro]).
I think in one recent CC someone even asked about antigen lifetime and Gold or Urdal quoted a "shelf life" as if
it were somekind of known number like the speeed of
light. Since they don't know how it works and there is
some literature suggesting that immunological properties
change during storage, you would think they would have someone actually looking at this.

Simply relegating their only science- cd54- to a legal role when the efficacy was so questionable was a big blunder. The way Urdal was talking it was "clinically meaningful" or words to the effect that it meant something to patients.

Does anyone know if Gold is showing that cartoon at investor presentations? You would think he would be highlighting the
problems ( opportunities ) and explaining how they are attacking them to create real value ( patents that lead to optimized products and spark the interest of potential collaborators that don't want to make a career out of cartoon MOA's).